Ask AI

Pharmacist-Led Support in Relapsed/Refractory CLL

Case Challenge
Case Challenge Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: June 29, 2026

Expiration: December 28, 2026

See Activity Collection

Treatment selection after covalent BTK inhibitor progression in relapsed/refractory CLL requires balancing emerging clinical evidence with specific patient comorbidities, treatment burden, monitoring requirements, and patient preferences. In this interactive case, pharmacists will explore considerations for sequencing pirtobrutinib and venetoclax-based therapy, managing safety and adherence challenges with these treatment options, and applying strategies for involving patients and their caregivers in shared decision-making to support individualized care.

Pharmacist Support in RR CLL

Pre Assessment

Assess your current knowledge and clinical approach before beginning your Case Challenge.
1.

For a patient with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) who is choosing between continuous oral therapy and a fixed-duration venetoclax-based regimen, which patient-centered factor should be discussed to support quality of life and engagement in care?

2.

Based on the BRUIN CLL-321 trial, which counseling point best reflects the clinical implication of pirtobrutinib for this patient?